WO2002063302A1 - Technique permettant de reduire l'interference de l'heparine dans des essais diagnostic de la troponine cardiaque - Google Patents
Technique permettant de reduire l'interference de l'heparine dans des essais diagnostic de la troponine cardiaque Download PDFInfo
- Publication number
- WO2002063302A1 WO2002063302A1 PCT/US2002/003713 US0203713W WO02063302A1 WO 2002063302 A1 WO2002063302 A1 WO 2002063302A1 US 0203713 W US0203713 W US 0203713W WO 02063302 A1 WO02063302 A1 WO 02063302A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heparin
- antagonist
- antibody
- moiety
- troponin
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
Definitions
- the present invention relates to assays for diagnostic testing. More particularly, the invention is directed to processes for reducing anticoagulant interferences in diagnostic tests, such as diagnostic immunoassays for cardiac Troponin
- Cardiac Troponin is a complex of three proteins of the thin filament of muscle. It is a muscle protein which functions to regulate muscle contraction.
- Cardiac Troponin I measurement has become the method of choice in detection of cardiac muscle damage because it's structure in heart muscle is unique muscle found in other parts of the body. The measurement has been facilitated by the generation of antibodies directed to the cardiac specific regions of Troponin I and incorporating these into commercially available assays. The major issue with these assays is that there is a lack of both standardization and correlation among methods. (Wu, A.H.B. Laboratory and Near Patient Testing for Cardiac Markers. J. Clin Ligand Assay, 22: 32-27 (1999)).
- heparin binds to cardiac Troponin I (cTNI) via a charge- charge interaction.
- cTNI cardiac Troponin I
- Heparin is frequently found in blood derived as a compound in samples because it is used as an anti-coagulant for sample collection or it is being used as a treatment in cardiac patients.
- the interaction of heparin with both free and complexed Troponin I can further complicate the assay results. It is reported by one manufacturer that the bias seen with heparin samples is 30% lower than in serum or other plasma samples (Dade Behring Opus plus Troponin I instructions for use). Consequently, it would be desirable if such interference could be overcome in order to provide a more accurate result. It would also be desirable if the correlation of different assay methods could be improved with the elimination of an interfering factor.
- the present invention is directed to a process for reducing heparin anticoagulant interference binding in an antibody-antigen diagnostic assay, such as a diagnostic assay for cardiac Troponin I.
- the process utilizes a moiety, such as a highly charged peptide, which competes with heparin at the antibody-antigen binding site.
- the moiety is a heparin antagonist such as a protamine salt or hexadimethrine bromide (polybrene).
- the invention relates to a process for increasing the sensitivity of an antibody-antigen diagnostic assay for cardiac Troponin I.
- the process utilizes a moiety such as a highly charged peptide which competes with heparin at the antibody-antigen binding site.
- the moiety is a charged peptide with a sequence similar to the native sequence but sufficient different to allow for a specific antibody-antigen reaction.
- the moiety is a heparin antagonist, and most preferably, the moiety is a protamine salt such as protamine sulfate or polybrene.
- the present invention is directed to a quantitative strip base immunoassay such as a quantitative strip base luminescent immunoassay to be used in the point of care environment.
- the immunoassay is useful for the testing for indications of acute myocardial infarction.
- the immunoassay can be utilized in conjunction with a moiety which competes with heparin at the antibody-antigen binding site or the moiety can be included in strip based immunoassay, such as with a solubilized substrate, etc.
- the invention accordingly comprises several components or steps and the relation of one or more of such components or steps with respect to each of the others and the article possessing the features, properties, and the relation of elements exemplified in the following detailed disclosure.
- BRIEF DESCRIPTION OF THE DRAWINGS [00011]
- the invention may take form in various components and arrangements of components and in various steps and arrangements of steps.
- the drawings are only for purposes of illustrating preferred embodiments and are not to be construed as limiting the invention.
- Fig. 1 is a listing of the skeletal and cardiac amino acid sequences for human Troponin I;
- Fig. 2 is a chart illustrating the kinetics of cardiac Troponin I in three human matrices
- Fig. 3 is a graph showing the effect of protamine against heparine using an immunoassay for cardiac Troponin I;
- Fig. 4 is a chart demonstrating the effect produced by the heparin antagonists, polybrene and protamine, on an immunoassay for cardiac Troponin I;
- Fig. 5 is an illustration of quantitative strip based luminescent immunoassay containing, or utilized in conjunction with, a heparin antagonist.
- SeraCare, San Diego CA were compared in spike and recovery experiments using human cTNI (Hytest, Finland) preparations at estimated values of 25, 50 and 75 ng/ml concentrations.
- Recovery in a prototype cTNI assay (Immunomatrix, Gaithersburg, MD) showed between 50 and 91% lower values in the heparinized plasma than the fresh frozen plasma.
- an examination of the kinetics of binding was performed using heparinized plasma (SeraCare, San Diego), heparinized plasma with the addition of 2mg/ml protamine sulfate salt (Sigma, St. Louis MO) and serum (in house pool) all spiked with 20ng/ml of human cTNI (Hytest, Finland).
- heparin antagonists There are other heparin antagonists available commercially.
- polybrene hexadimethrine bromide
- cTNI immunomatrix prototype cTNI assay as described in example 3.
- samples prepared from heparinized plasma with either 2 mg/ml protamine or 1 mg/ml polybrene and spiked with levels of cTNI at 0, a low concentration (1 ng/ml) or a high concentration (50 ng/ml) an evaluation of the effect of these two heparin antagonists was made.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26689201P | 2001-02-07 | 2001-02-07 | |
US60/266,892 | 2001-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002063302A1 true WO2002063302A1 (fr) | 2002-08-15 |
Family
ID=23016414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/003713 WO2002063302A1 (fr) | 2001-02-07 | 2002-02-07 | Technique permettant de reduire l'interference de l'heparine dans des essais diagnostic de la troponine cardiaque |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2002063302A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108254579A (zh) * | 2018-01-31 | 2018-07-06 | 济南景正医疗器械有限公司 | 制备一种抗干扰能力强的高密度脂蛋白胆固醇检测试剂盒 |
JPWO2017179611A1 (ja) * | 2016-04-13 | 2019-02-21 | 株式会社Lsiメディエンス | 硫酸化多糖類を用いた免疫学的測定法 |
US10670611B2 (en) | 2014-09-26 | 2020-06-02 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5320812A (en) * | 1993-10-04 | 1994-06-14 | Becton, Dickinson And Company | Clot activating polyelectrolyte complex and blood collection assembly containing same |
US5677133A (en) * | 1993-02-17 | 1997-10-14 | Cardiovascular Diagnostics, Inc. | Dry chemistry cascade immunoassay and affinity assay |
WO1999040442A1 (fr) * | 1998-02-05 | 1999-08-12 | Bio-Rad Pasteur | Dosage des troponines sans interferences dues a l'heparine |
US6174686B1 (en) * | 1995-04-18 | 2001-01-16 | Biosite Diagnostics, Inc. | Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays |
-
2002
- 2002-02-07 WO PCT/US2002/003713 patent/WO2002063302A1/fr not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677133A (en) * | 1993-02-17 | 1997-10-14 | Cardiovascular Diagnostics, Inc. | Dry chemistry cascade immunoassay and affinity assay |
US5320812A (en) * | 1993-10-04 | 1994-06-14 | Becton, Dickinson And Company | Clot activating polyelectrolyte complex and blood collection assembly containing same |
US6174686B1 (en) * | 1995-04-18 | 2001-01-16 | Biosite Diagnostics, Inc. | Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays |
WO1999040442A1 (fr) * | 1998-02-05 | 1999-08-12 | Bio-Rad Pasteur | Dosage des troponines sans interferences dues a l'heparine |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10670611B2 (en) | 2014-09-26 | 2020-06-02 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
JPWO2017179611A1 (ja) * | 2016-04-13 | 2019-02-21 | 株式会社Lsiメディエンス | 硫酸化多糖類を用いた免疫学的測定法 |
EP3444612A4 (fr) * | 2016-04-13 | 2019-12-11 | LSI Medience Corporation | Dosage immunologique utlisant un polysaccharide sulfaté |
US11422128B2 (en) | 2016-04-13 | 2022-08-23 | Lsi Medience Corporation | Immunoassay employing sulfated polysaccharide |
CN108254579A (zh) * | 2018-01-31 | 2018-07-06 | 济南景正医疗器械有限公司 | 制备一种抗干扰能力强的高密度脂蛋白胆固醇检测试剂盒 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104634980B (zh) | 心肌肌钙蛋白i超敏检测试剂盒及超敏检测方法 | |
EP3258270A1 (fr) | Trousse de réactifs de détection ultra-sensible à la troponine i cardiaque et procédé de détection ultra-sensible associé | |
CA1223922A (fr) | Methodes de dosage | |
JPH0926423A (ja) | 不活性担体分子に対して複合体形成された被検体もしくはその部分配列を含む免疫アツセイで使用するための合成キヤリブレーター | |
JP2000509486A (ja) | 1段階オールインワン乾燥試薬イムノアッセイ | |
US5925533A (en) | Tropinin I calibrator and method of use thereof in a sandwich immunoassay | |
US8129132B2 (en) | Detection of autoantibodies reactive with pancreatic islet cell antigenic molecules and/or insulin | |
US6268481B1 (en) | Covalently coupled troponin complexes | |
WO2001035105A1 (fr) | Procede de mesure de la concentration serique d'asialoglycoproteine utile pour diagnostiquer les maladies hepatiques et trousse associee | |
JPH06502912A (ja) | アナライト変異体分析 | |
JPH02503714A (ja) | IgA腎臓病の診断のための方法及びキツト | |
US4722890A (en) | Quantitative assay for human terminal complement cascade activation | |
EP3818375A1 (fr) | Mesure d'auto-anticorps par dosage immunologique direct | |
WO2002063302A1 (fr) | Technique permettant de reduire l'interference de l'heparine dans des essais diagnostic de la troponine cardiaque | |
FI113567B (fi) | Menetelmä Downin syndrooman testaamiseksi | |
CN106366199A (zh) | 一种肌钙蛋白i单克隆抗体磁微粒及其制备方法和检测试剂盒 | |
WO1998054219A1 (fr) | Complexes de troponine couples de maniere covalente | |
CN112805565A (zh) | 对肝型脂肪酸结合蛋白质进行定量的方法、其定量用试剂盒、肾疾病的检查方法、其检查试剂盒及伴随诊断药 | |
Menzel et al. | Interaction of collagen with C1q via its collagen-like portion | |
WO1997008551A1 (fr) | Procedes et anticorps permettant la detection de creatine kinase | |
WO1998029726A2 (fr) | Procede de detection de la troponine i et de determination de sa concentration totale dans un echantillon biologique | |
EP1371986A1 (fr) | Diagnostic de la maladie d'Alzheimer basé sur le rapport entre hAbèta42 et hAbèta40 | |
CA1300808C (fr) | Dosage immunologique a polarisation de fluorescence et reactifs de mesure de la proteine c-reactive | |
Cormane et al. | Antibodies eluted from lymphoid cell membrane: Occurrence in certain varieties of scleroderma | |
Vuori et al. | The use of myoglobin/carbonic anhydrase III ratio as a marker for myocardial damage in patients with renal failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |